ClinicalTrials.gg
CompletedNCT04810143VAMSUpdated Dec 20, 2022

Tacrolimus Microsampling

An interventional study of Mitra Microsampler in Validate Volumetric Absorptive Microsampling (VAMS) Assay, sponsored by Children's Hospital Medical Center, Cincinnati. Completed at 1 site in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2019, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
1 Year to 21 Years
Sex
All
01

Study summary

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients who have undergone heart transplantation who meet eligibility requirements will be approached to participate in the study. The purpose of this study is to establish a reliable, home-based method for collecting samples as well as a standardized method for use of small-volume samples on both inpatients and outpatients.

02

Conditions studied

  • Validate Volumetric Absorptive Microsampling (VAMS) Assay
03

In context

Lead sponsor

Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 133 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 31 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pediatric, adolescent, or young adult patients ≥1 and ≤21 years of age

    1. Aim 1: All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits
    2. Aim 2: outpatient
  2. Currently taking tacrolimus

Exclusion criteria

Exclusion Criteria:

  1. Non-English-speaking patients
  2. Unable to access overnight delivery services (Aim 2 only)
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Aim 1

    All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test "real world" application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough.

    Device: Mitra Microsampler

  • Experimental
    Aim 2

    Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.

    Device: Mitra Microsampler

Interventions

  • DeviceMitra Microsampler

    an FDA Class I medical device for direct specimen collection of blood or other biological fluids

06

What researchers measure

Primary outcomes

  1. Accuracy of +/-10%

    A VAMS-based tacrolimus trough values will be accurate +/-10% when compared with standard whole blood values achieved via venipuncture.

    Time frame: 18-24 months from start of enrollment

07

Study locations

1 site
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04810143
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Oct 7, 2019
Primary completion
Jan 3, 2022
Completion
Jul 28, 2022
Last update
Dec 20, 2022

Study contacts

Thomas C Ryan
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion